newsfilter
← Latest News
GlobeNewswire·

Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

SER-155 Phase 1b placebo-controlled clinical results demonstrated significant reduction in both bacterial bloodstream infections and systemic antibiotic exposure, as well as lower incidence of febrile neutropenia, as